Alpha-1 Antitrypsin Deficiency Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
Conditions: SR aGvHD; Acute-graft-versus-host Disease; Steroid Refractory Acute Graft Versus Host Disease; Graft-versus-host-disease; Graft Vs Host Disease; Alpha 1-Antitrypsin Deficiency; Alpha-1 Proteinase Inhibitor; Alpha-1 Protease Inhibitor Deficiency; Acute Graft-Ve rsus-Host Reaction Following Bone Marrow Transplant Intervention: Drug: Glassia Sponsors: Impatients N.V. trading as myTomorrows; Kamada, Ltd. Available - verified May 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2017 Category: Research Source Type: clinical trials